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Anthracycline-related 
cardiotoxicity: risk factors 
and therapeutic options in 
childhood cancers
ABSTRACT
Anthracyclines play an important role in chemotherapeutic regimens for a wide spectrum of childhood tumors, but they 
can cause cytotoxic damage to cardiac cells, especially in combination with radiotherapy. Furthermore, cardiotoxicity 
increases with the cumulative dose and may lead to congestive heart failure and cardiomyopathy. Other factors, including 
age, pre-existing cardiac disease, length of follow-up, gender, route of administration, concomitant exposure to some 
chemotherapeutic drugs, trisomy 21 and black race, play a role in increasing the risk of cardiac dysfunction. The prevention 
of anthracycline-induced cardiotoxicity is mandatory as children are expected to survive for decades after being cured of 
their cancer. The purpose of this work is to point out the major risk factors of cardiotoxicity in children and to summarize 
some strategies to limit or prevent this complication and to treat the development of acute heart failure. 
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Introduction 
Anthracyclines (daunomycin, doxoru-
bicin, epirubicin, idarubicin) are among 
the most effective antineoplastic drugs 
and have gained widespread use in the 
treatment of numerous solid tumors 
and hematological malignancies. 
These drugs belong to the class of anti-
neoplastic antibiotics which interfere 
with cell replication, by acting on DNA 
at several levels showing an effect in 
every phase of the cell cycle. 
Doxorubicin and daunomycin (figure 1) 
are the more commonly used anthra-
cyclines in clinical practice; they are 
administered only by intravenous infu-
sion and metabolized by the liver. Their 
main route of excretion is through bile, 
while urinary elimination accounts for 
approximately 1/6 of the total amount.
Although anthracyclines exhibit a range 
of toxic effects including myelosup-
pression, mucositis and hair loss, car-
diotoxicity may be permanent and pro-
gressive.
Therefore, the oncologist should take 
into account the risk of cardiac toxicity 
due to anthracyclines as a potential 
cause of severe morbidity in survivors 
of childhood cancers, as children will 
have a chance of long-term survival 
once cured from cancer. We reviewed 
                    Doxorubicin                                             Daunomycin
Figure 1.  Structures of the anthracyclines currently used. 
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the spectrum of clinical presentations of 
anthracycline-induced toxicity, focus-
ing on acute heart failure.     
Mechanism of 
cardiotoxicity 
Three mechanisms are involved in the 
cytotoxic action of anthracyclines:
1. high affinity binding to DNA, via 
nucleic intercalation, which causes inhi-
bition of DNA and RNA synthesis and 
cleavage of DNA strands by alterations 
of topoisomerase II
2. binding to the cell membrane which 
alters its normal fluidity and transport 
of ions
3. semiquinonic and oxygen free radi-
cal production, via reduction enzymatic 
reaction.
Despite the wide use of anthracyclines, 
their cardiotoxic mechanism is still not 
completely understood. The most 
common hypothesis is the formation 
of free radicals and superoxides. (1-4) 
Cardiac cells are more susceptible to 
free radical damage because of their 
highly oxidative metabolism and rela-
tively poor antioxidant defences. (5) 
This mechanism was originally pro-
posed as the basis for anthracyclines-
related cardiotoxicity (6), but some 
additional variables are involved, such 
as the interaction of the anthracyclines 
with iron. 
Epidemiology 
In the literature, there is wide variation in 
the reported frequency of both clinical 
and subclinical cardiotoxicity. 
In children, early onset cardiotoxicity 
seems to occur less frequently than late 
cardiac damage. There is a relatively 
low rate of early clinical cardiotoxicity, 
since only 1.6% of all children treated 
with anthracyclines have cardiotoxic 
effects. (7)
The prevalence of late subclinical car-
diac damage has been reported to 
be more than 57% at a median of 6.4 
years after treatment among survivors 
of childhood cancers (8) and the inci-
dence of clinical heart failure as high 
as 16%, 0.9 to 4.8 years after treat-
ment. (9) Differences in study popula-
tion, treatment protocols, and duration 
of follow-up could account for this wide 
variability. 
The risk of cardiotoxic effects occurring 
about 15 years after treatment with a 
mean cumulative dose of anthracy-
clines of 300 mg/m² is estimated to be 
approximately 5%. (10) 
Risk of mortality from cardiac-related 
events is 8 times higher for long term 
survivors than for the normal popula-
tion. (11,12)
Risk factors for 
anthracycline-induced 
cardiotoxicity
Several risk factors for anthracycline-
induced cardiotoxicity appear to be 
involved in the development of clini-
cal and subclinical cardiotoxic effects. 
Patients should be screened for risk 
factors and an attempt to modify them 
should be made.
The most important risk factors for 
anthracycline-induced cardiotoxicity 
are summarized in table 1.
Total cumulative dose of anthracyclines 
is the most significant risk factor for 
cardiac dysfunction. (13) The maximum 
cumulative dosage linked to minimal 
cardiotoxicity varies among the differ-
ent anthracyclines and a safe dose, not 
resulting in late cardiac injury, has not 
been established. 
The usual dosage of doxorubicin is 60-
75 mg/mq, every 3 weeks. (14) Above 
a cumulative dose of 450-500 mg/mq, 
cardiomyopathy and congestive heart 
failure occur frequently.
Younger age predisposes to greater 
cardiotoxicity. (15) Children seem to be 
more sensitive to the cardiac adverse 
effects of the anthracyclines. However, 
in children mechanisms leading to late 
cardiotoxicity differ from those causing 
acute cardiotoxicity in adults (13,16) 
and anthracycline infusions were used 
in order to lower peak drug concentra-
tion, reducing cardiotoxicity. 
Hypertension and any significant pre-
existing cardiac disease increase the 
Table 1.  Risk factors for anthracyclines-related cardiotoxicity.
RISK FACTORS                  EFFECTS
Abnormal cardiac function
Higher risk for chronic cardiac 
dysfunction
Cumulative dose
The most significant risk factor for 
cardiac dysfunction
Age
Younger age predisposes to greater 
cardiotoxicity
Lenght of infusion
Infusions do not differ from bolus 
modality in children.
Sex Females are more vulnerable
Irradiation






Black race Higher risk of early clinical cardiotoxicity
Trisomy 21 Higher risk of early clinical cardiotoxicity
Length of follow-up
A longer follow-up increases the risk of 
cardiotoxicity
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risk of clinically apparent cardiac dis-
ease. (17)
Females are more vulnerable than 
males for comparable doses. (7) 
Concomitant mantle irradiation is a 
predisposing factor, but it is not clear 
whether it is additive or synergistic to 
treatment with anthracyclines. (15) 
Cardiac radiation exposure clearly 
increases the sensitivity of the heart 
to anthracyclines. Concomitant expo-
sure to cyclophosphamide, bleomycin, 
vincristine, amsacrine or mitoxantrone 
may predispose to cardiotoxicity. (7)
Black race (7) and trisomy 21(7) increase 
the risk of early cardiotoxicity. 
An increased incidence of cardiac fail-
ure and severe cardiac abnormalities 
more frequently occur with longer fol-
low-up. (15)
Clinical presentation
The clinical presentation of anthracy-
cline-induced toxicity can be divided 
into: 
- acute or subacute: heart damage that 
develops immediately after the infusion 
of the drug or within a week of therapy
- early onset chronic progressive car-
diotoxicity: a depression of myocar-
dial function which occurs during the 
treatment or within the first year after 
treatment
- late onset chronic progressive cardio-
toxicity:  this occurs at least 1 year after 
the end of treatment.
Clinically significant cardiotoxicity dur-
ing or in the first year following initial 
chemotherapy is rare, occurring in less 
than 1% of children. (13) Instead, late 
subclinical abnormalities of left ventric-
ular structure and function in long-term 
survivors of childhood cancer are com-
mon. (13,16,18-23) Late onset effects 
can occur up to 20 years after comple-
tion of anthracycline therapy. (19)
Early cardiotoxicity is presumably 
related to myocyte damage or death 
resulting in depressed left ventricular 
contractility (13,16,24); while late car-
diotoxicity is due to depressed con-
tractility and thin left ventricular wall 
resulting in increased wall stress and 
decreased left ventricular systolic func-
tion. (13,16,24)
Acute heart failure related 
to anthracycline induced 
cardiotoxicity
Acute heart failure in children receiving 
anthracyclines can occur within one 
week of drug infusion, thus without the 
presence of chronic cardiac damage, 
or as acute decompensated heart fail-
ure in the setting of established anthra-
cycline-induced cardiomyopathy. The 
second scenario is more common and 
develops when underlying compensa-
tory mechanisms that sustain normal 
cardiac function in the setting of chronic 
heart failure, are exhausted. 
Acute changes during anthracycline 
infusion range from minor electrocar-
diographic abnormalities (non-specific 
ST-T changes and QT prolongation) 
to fatal ventricular arrhythmias. Echo-
cardiography can reveal LV systolic 
dysfunction that is usually transient, 
but a few patients may experience 
acute and potentially fatal congestive 
heart failure while on therapy. (25) In 
its more extreme form, this acute injury 
can include a pericarditis-myocarditis 
syndrome with onset of fever, pericar-
ditis and congestive heart failure. This 
syndrome can occur at low cumulative 
doses of doxorubicin and can have a 
fatal outcome. (26)
The Ross Classification (27) was devel-
oped for grading heart failure in infants 
and younger children (Grade I: asymp-
tomatic. Grade II: mild tachypnea or 
diaphoresis with feeding in infants; 
dyspnea on exertion in older children. 
Grade III: marked tachypnea or diapho-
resis with feeding in infants; prolonged 
feeding times with growth failure due to 
heart failure; in older children, marked 
dyspnea on exertion. Grade IV:  symp-
toms such as tachypnea, retractions, 
grunting, or diaphoresis at rest).
Breathlessness, a cardinal manifesta-
tion of left ventricular failure, may pres-
ent, in order of severity, as:
- exertional dyspnea (as left ventricu-
lar failure  progresses, the intensity of 
exercise resulting in breathlessness 
declines progressively)
- orthopnea (dyspnoea that develops in 
the recumbent position and is relieved 
by elevation of the head with pillows)
- paroxysmal nocturnal dyspnoea (feel-
ing of severe anxiety and suffocation 
and gasps for breath)
- acute pulmonary edema (is consid-
ered a clinical emergency and occurs 
as initial presentation of heart failure 
or as an aggravating condition of heart 
failure. Presents as extreme breathless-
ness that develops suddenly, the respi-
ratory rate is elevated, the alae nasi are 
dilated and there is inspiratory retrac-
tion of the intercostal space and use of 
accessory muscles of respiration; the 
skin is usually cold and cyanotic reflect-
ing low cardiac output. On auscultation 
there are many lung sounds with ronchi, 
wheezes and fine crepitant rales that 
appear at first over the lung bases but 
then extend upward to the apices; car-
diac auscultation is difficult because of 
the respiratory sounds).
Cardiomegaly occurs in patients with 
chronic systolic heart failure. Also, pro-
todiastolic sounds (gallop sounds) are 
audible in patients with heart failure.
In mild right-sided heart failure, the jug-
ular venous pressure may be normal at 
rest but rises to abnormal levels with 
compression of the right upper quad-
rant (hepatojugular reflux).
The liver often enlarges before overt 
edema develops and it may remain 
so even after other symptoms of right-
sided heart failure have disappeared.
Although a cardinal manifestation of 
heart failure, edema does not correlate 
well with the level of systemic venous 
pressure. Edema in heart failure is usu-
ally symmetrical and pitting and gener-
ally occurs in the dependent portions 
of the body. Late in the course of heart 
failure, edema becomes massive and 
generalized (anasarca) and weight gain 
associated with anasarca correlates 
with attenuation of electrocardiograph-
ic voltage.
In severe heart failure prolonged sodium 
restriction coupled with intensive diuret-
ic therapy and the inability to excrete 
free water, may lead to dilutional hypo-
natremia. Serum potassium levels are 
usually normal, although prolonged 
administration of kaliuretic diuretics 
may result in hypokalemia. Other com-




Proteinuria and a high urine specific 
gravity are common findings in heart 
failure. 
Arrhythmias likely to require acute treat-
ment in patients with heart failure include 
atrial tachyarrhythmias with a rapid 
ventricular rate, paroxysmal supraven-
tricular tachycardia, junctional ectopic 
tachycardia and sustained ventricular 
tachycardia. Synchronized cardiover-
sion/defibrillation should be considered 
for treatment of either supraventricular 
or ventricular arrhythmias if hemody-
namic collapse is imminent. (28, 29)
Management of episodes of acute heart 
failure includes therapy with diuretics, 
support of pump function with positive 
inotropic agents and/or, if extremely 
severe, with mechanical devices to the 
extent necessary to provide adequate 
perfusion of critical organs. 
Mechanical circulatory support has 
become an important addition to the 
treatment armamentarium for the infant 
or child with acutely decompensated 
heart failure and low cardiac out-
put unresponsive to pharmacologic 
manoeuvres. Mechanical support main-
tains end-organ function and reduces 
myocardial oxygen requirements dur-
ing a critical period of recovery from a 
cardiac insult.
Conclusion
Anthracycline-induced cardiotoxicity is 
a limiting factor in the use of anthracy-
clines, especially when predisposing 
factors are present. Therefore, the pres-
ence of risk factors should be investi-
gated before starting therapy. Indeed, 
prompt recognition of modifiable risk 
factors can help reduce cardiac dam-
age. 
Another goal is to monitor the patient 
for the rapid development of initial signs 
of cardiac damage. Serial monitoring 
(echocardiogram, electrocardiogram 
and holter) of cardiac function in chil-
dren receiving anthracyclines allows 
early identification of heart damage. The 
monitoring schedule varies between 
protocols. Frequency and timing of 
tests depends on the child’s age at time 
of exposure, cumulative dose of anthra-
cyclines, chest irradiation, presence of 
cardiac abnormalities, symptoms, and 
other stressors. (30) Generally, all sur-
vivors treated with cardiotoxic therapy 
should be screened, symptomatic or 
not. The protocol for the assessment 
of cardiac function in these patients 
should be based on a multi-modality 
approach. Acute heart failure is a dan-
gerous complication that can develop 
either as acute cardiotoxicity, within 
one week of drug infusion, or as acute 
decompensated chronic heart failure, 
often requiring therapy with diuretics 
and support of pump function with posi-
tive inotropic agents.
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